合成ヘパリン代用剤による血管新生の制御
J Folkman1, P B Weisz, M M Joullié
1Department of Surgery, Harvard Medical School, Boston, MA 02115.
まとめ
研究者らは,強力な血管新生阻害剤であるβ-サイクロデクストリンテトラデカスルファートを発見し,ステロイドと連携して作用しています. この化合物はヘパリンと比較して,抗血管新生効果が著しく強化され,血管の成長によって引き起こされる疾患に対する潜在的な治療効果を提供します.
科学分野:
- バイオケミストリー バイオケミストリー
- 腫瘍学 腫瘍学
- 血管生物学 血管生物学
背景:
- 持続的な毛細血管血管の成長は,がんを含む多くの病気の特徴です.
- 新しい血管の形成である血管新生は,腫瘍の成長に不可欠です.
- 安全で効果的な血管新生阻害剤の開発は,治療的応用において極めて重要です.
研究 の 目的:
- 効果的な血管新生阻害剤を特定するために.
- 血管新生に作用する化合物の相乗効果を探求する.
- 血管新生に依存する疾患に対する潜在的な治療薬の評価.
主な方法:
- ヘパリンとステロイドの相乗効果の抗血管新生効果を調査した.
- ベータ・サイクロデクストリン・テトラデカスルファートは,ステロイドと併用してヘパリン代用剤としてテストされています.
- チップの胚バイオアッセイとウサギの角膜新血管化モデルを使用しました.
主要な成果:
- ステロイドと組み合わせたベータ・サイクロデクストリン・テトラデカスルファートは,鶏の胚においてヘパリンよりも100~1000倍の抗血管新生効果を示した.
- この組み合わせ療法により,ウサギの角膜新血管化モデルにおけるステロイドの抗血管性効果が強化された.
- 循環性オリゴサッカリドは,強力な血管新生阻害剤としての有意な可能性を示しました.
結論:
- ベータ・サイクロデクストリン・テトラデカスルフェートは,ステロイドと併用すると,非常に効果的な血管新生阻害剤です.
- この化合物は,病的な血管新生を制御する有望な治療候補である.
- この相乗効果の組み合わせに関するさらなる研究は,さまざまな疾患に対する新しい治療法につながる可能性があります.
関連する概念動画
Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...


